Digostics secures £500k through Crowdcube to expand its at-home diabetes testing platform.
.png)
The health tech company surpassed £500k on Crowdcube with backing from more than 100 investors.
Digostics develops GTT at home, an oral glucose intolerance test designed to replace clinic visits. The CE marked platform supports diabetes screening for patients in the UK and international markets.
Digostics has secured £500k in seed funding via the Crowdcube platform, drawing backing from more than 100 investors. The capital will support the expansion of its home-use glucose testing kit, which provides an alternative to traditional clinic-based glucose tolerance tests.
The company has already rolled out its digital platform across multiple NHS trusts for gestational diabetes screening and delivered over 5000 tests. Alongside its UK presence, Digostics is pursuing early commercial traction in international markets including the United Arab Emirates and Singapore.
From the founder
"Reaching the £500,000 threshold is an exciting moment, one that reflects investor belief in our mission to make diabetes screening simpler, earlier, and more accessible. With healthcare systems under increasing pressure, innovations like GTT@home can reduce clinical burden while improving patient experience and outcomes."
James Jackson
CEO and Founder at Digostics
Investors
Categories
About the company
.png)
Digostics
Digostics builds an at-home oral glucose tolerance test for diabetes detection.